Who
Brian T. Powl
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Kura Oncology; Chief Commercial Officer, Fate Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $1.3M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Jun 2022
- Last trade
- 29 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $166K15,430 at $10.75 | filing |
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $166K15,430 at $10.75 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $95K9,020 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $84K8,000 at $10.56 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $95K9,020 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $84K8,000 at $10.56 | filing |
| 21 Aug 2026filed 24 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $52K4,345 at $11.89 | filing |
| 21 Aug 2026filed 24 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $52K4,345 at $11.89 | filing |
| 21 May 2026filed 22 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $110K10,000 at $11.00 | filing |
| 21 May 2026filed 22 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $110K10,000 at $11.00 | filing |
| 19 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $3,122339 at $9.21 | filing |
| 19 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $3,122339 at $9.21 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $41K4,842 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $13K1,572 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $41K4,842 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $13K1,572 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Brian T. Powl; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.